DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders
ECCO '19 Copenhagen
2019
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU
ECCO '19 Copenhagen
2019
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
ECCO '19 Copenhagen
2019
DOP46: Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
ECCO '19 Copenhagen
2019
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
ECCO '19 Copenhagen
2019
DOP48: Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study
ECCO '19 Copenhagen
2019
DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II
ECCO '19 Copenhagen
2019
DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study
ECCO '19 Copenhagen
2019
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
ECCO '19 Copenhagen
2019
DOP52: Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
ECCO '19 Copenhagen
2019
DOP53: Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis
ECCO '19 Copenhagen
2019
DOP54: Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
ECCO '19 Copenhagen
2019
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing
ECCO '19 Copenhagen
2019
DOP56: Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
ECCO '19 Copenhagen
2019
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST&UC
ECCO '19 Copenhagen
2019
DOP58: IdeaL: a multi-centre prospective infliximab dose to level pharmacokinetic study during induction in paediatric Crohn’s disease
ECCO '19 Copenhagen
2019
DOP59: Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease
ECCO '19 Copenhagen
2019
DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s
ECCO '19 Copenhagen
2019